Can cefdinir be taken together with ondansetron (Zofran) safely?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Cefdinir and Ondansetron (Zofran) Be Taken Together?

Yes, cefdinir and ondansetron can be safely taken together—there are no known drug interactions between these medications, and they are commonly co-administered in clinical practice without safety concerns.

Evidence for Safety

No Direct Drug Interactions

  • Neither the FDA drug label for cefdinir nor clinical pharmacology data identify ondansetron as having any interaction with cefdinir 1.
  • Cefdinir is not appreciably metabolized and is eliminated primarily via renal excretion as unchanged drug, making drug-drug interactions unlikely 1.
  • Ondansetron is metabolized hepatically via cytochrome P450 enzymes, while cefdinir does not undergo significant hepatic metabolism, eliminating the potential for metabolic interactions 2.

Common Clinical Scenarios

These medications are frequently used together in practice:

  • Pediatric gastroenteritis with bacterial infection: Children may receive cefdinir for bacterial infections (such as otitis media or sinusitis) while simultaneously receiving ondansetron for vomiting 3, 4, 5.
  • Post-chemotherapy infections: Patients receiving ondansetron for chemotherapy-induced nausea may develop infections requiring cefdinir treatment 6.

Practical Considerations

Timing of Administration

  • Cefdinir can be taken without regard to food, though food slightly reduces absorption (16% decrease in Cmax with capsules, 44% with suspension)—this reduction is not clinically significant 1.
  • Ondansetron should be given at least 30 minutes before anticipated nausea when used prophylactically, as peak concentration occurs 0.5-2 hours after oral ingestion 2.
  • There is no need to separate the administration times of these two medications.

Monitoring

  • Watch for cefdinir-related diarrhea (occurs in 15% of adults and 8% of children), which could be mistaken for worsening gastroenteritis if ondansetron is being used for GI symptoms 1.
  • Both medications are generally well-tolerated with mild, self-limiting adverse effects 1, 2.

Special Populations

  • Pediatric patients: Both medications are FDA-approved and commonly used in children, with cefdinir dosed at 14 mg/kg/day and ondansetron at 0.1 mg/kg 1, 5, 7.
  • Renal impairment: Cefdinir requires dose adjustment in severe renal impairment (creatinine clearance <30 mL/min), while ondansetron does not require renal dose adjustment 1, 2.
  • Hepatic impairment: Ondansetron clearance may be reduced in severe hepatic impairment, but cefdinir is unaffected 2.

Clinical Bottom Line

There is no contraindication or clinically significant interaction between cefdinir and ondansetron. They can be prescribed and administered together safely across all age groups. The only consideration is distinguishing cefdinir-induced diarrhea from the underlying condition being treated with ondansetron, but this does not preclude their concurrent use.

References

Research

Ondansetron clinical pharmacokinetics.

Clinical pharmacokinetics, 1995

Guideline

the diagnosis and management of sinusitis: a practice parameter update.

Journal of Allergy and Clinical Immunology, 2005

Research

Oral ondansetron for paediatric gastroenteritis in primary care: a randomised controlled trial.

The British journal of general practice : the journal of the Royal College of General Practitioners, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.